Instituto Médico de la Fundación Estudios Clínicos - Rosario
El Instituto Médico de la Fundación Estudios Clínicos es una institución dedicada al desarrollo de las ciencias médicas, apoyando toda inquietud científica. Promueve el desarrollo de Estudios Clínicos, entendiéndolo como oportunidad y posibilidad para el desarrollo de medicamentos o procedimientos que permitan el mejoramiento de la calidad de vida de los pacientes.Instituto Médico de la Fundación Estudios Clínicos - Rosario
Italia 428, Rosario - Santa Fe
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Investigador PrincipalTomas Alvarez
Sub investigadoraDiego Ferreyra
Investigador PrincipalMaria Fernanda Maccario
Sub investigadoraEvangelina Montani
Investigador PrincipalMercedes Schiavoni
Investigador PrincipalClara Bernardini
Investigador PrincipalMaria Noelia Bersano
Investigador PrincipalEzequiel Vottero
Sub investigadoraMaria Sol Dichiara
Investigadora PrincipalGustavo Braidot
Investigador PrincipalJuan Andrés Oddino
Investigador PrincipalMartin Camilo Azum
Investigador PrincipalJavier Travella
Investigador PrincipalGabriel Garbaos
Investigador PrincipalBetiana Romitelli
Sub investigadoraAna Sol Capelleti
Investigador PrincipalGerman Antonio Arce
Investigador PrincipalNadia Brandan
Investigador PrincipalGabriel Gattolin
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer - OVELIA - Tolmar Inc.See more
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) - CAPItello-292 - AstraZenecaSee more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - TROPION-Breast05 - AstraZenecaSee more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) - MK 2870-010 - Merck Sharp & Dohme LLCSee more
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) - DYNASTY-Breast02 - BioNTech SESee more
Asthma
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma - FLASH - AstraZenecaSee more
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma - INC 54707-208 - Incyte CorporationSee more
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) - VALIANT - Upstream Bio Inc.See more
Lung cancer
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.See more
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) - WU-KONG28 - Dizal PharmaceuticalsSee more
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) - MK-1084-004 - Merck Sharp & Dohme LLCSee more
Pulmonary fibrosis
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease - Moonscape - Genentech, Inc.See more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis - Bristol-Myers SquibbSee more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - Bristol-Myers SquibbSee more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease - Moonscape - Genentech, Inc.See more
Urticaria
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines - Novartis PharmaceuticalsSee more
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex TherapeuticsSee more
Bile Duct Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - JZP598-302 - Jazz PharmaceuticalsSee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Crohn's disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease - CULTIVATE - Arena PharmaceuticalsSee more
Gastrointestinal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) - REJOICE-GI01 - Merck Sharp & Dohme LLCSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Leukemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Lymphoma
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Multiple myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) - SUCCESSOR-2 - Bristol-Myers SquibbSee more
Nephropathy
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression - IMAGINATION - Hoffmann-La RocheSee more
Non-Hodgkin Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - waveLINE-010 - Merck Sharp & Dohme LLCSee more
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) - ESsCAPE - BiotestSee more
Renal disease
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) - CONNEX-1 CONNEX-2 CONNEX-3 - Boehringer IngelheimSee more
Skin cancer
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007). - V940-007 - Merck Sharp & Dohme LLCSee more
Ulcerative colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) - LUCENT 3 - Eli Lilly and CompanySee more
